Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P41597

UPID:
CCR2_HUMAN

ALTERNATIVE NAMES:
Monocyte chemoattractant protein 1 receptor

ALTERNATIVE UPACC:
P41597; A0AVQ3; B2RMT0; O95950; Q4VBL2

BACKGROUND:
The C-C chemokine receptor type 2 (CCR2) is integral to the immune system's response, acting as a receptor for chemokines such as CCL2. It triggers chemotaxis in monocytes and macrophages, and is crucial for T-cell inflammatory cytokine expression and differentiation. CCR2's involvement extends to neuropathic pain mediation and enhancing NMDA-mediated synaptic transmission, highlighting its significance in both immune response and neural processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of C-C chemokine receptor type 2 offers a promising avenue for developing treatments for inflammation, neuropathic pain, and potentially, HIV-1 management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.